文献速递艾滋病与性传播感染

比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为初治方案和转换策略在病毒学抑制的HIV感染者中的长期结局:来自ICONA队列的数据

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

ICONA观察性队列研究评估比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(BIC/FTC/TAF)在临床试验中代表性不足人群中作为初治或转换方案的有效性。初治者933例,中位随访69.8周,9.6%发生治疗失败;转换者1655例,中位随访146.3周,6.6%发生治疗失败。总体耐受性和病毒学有效性良好,但初治中年龄>50岁和晚期HIV疾病者治疗失败风险更高。

要点

  • 初治者中位随访69.8周,9.6%发生治疗失败;转换者中位随访146.3周,6.6%发生治疗失败。
  • 初治者中年龄>50岁治疗失败风险高1.83倍(95%CI:1.19-2.83),晚期HIV疾病者高2.21倍(95%CI:1.53-3.82)。
  • 转换者中,各关注组(年龄>50岁、女性、晚期HIV疾病)的治疗失败、毒性停药和病毒学失败风险无差异。

核心结论

  • 在真实世界中,BIC/FTC/TAF对初治和经治HIV感染者总体耐受性良好且病毒学有效。
  • 年龄>50岁的初治感染者和晚期HIV疾病初治者可能应答较差,疾病负担可能影响疗效。

研究设计与样本

  • ICONA观察性队列研究,纳入开始BIC/FTC/TAF作为初始治疗或转换方案的HIV感染者。
  • 初治组933例,转换组1655例(转换组均为病毒学抑制者)。
  • 主要终点为治疗失败时间(新发艾滋病/死亡、病毒学失败或毒性/失败停药);次要终点为毒性停药时间和病毒学失败时间。

主要发现

  • 初治组中位随访69.8周,89例(9.6%)发生治疗失败。
  • 初治组中,年龄>50岁者治疗失败风险高1.83倍(95%CI:1.19-2.83);晚期HIV疾病者高2.21倍(95%CI:1.53-3.82);性别间无差异。
  • 转换组中位随访146.3周,1655例中109例(6.6%)发生治疗失败。
  • 转换组中,各关注组(年龄>50岁、女性、晚期HIV疾病)的治疗失败、毒性停药和病毒学失败风险均无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. METHODS: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as switching regimen while virologically suppressed. Primary endpoint was time to treatment failure (TF): new AIDS/death or virological failure (VF) or discontinuation for toxicity/failure. Secondary endpoints were time to treatment discontinuation for toxicity (TDT) and to VF. Groups of interest were those aged >50 years, female sex, and advanced HIV disease at first ART start. Probability of the events overall and according to groups and adjusted HR for every endpoint were calculated by Kaplan-Meier curves and Cox regression models. RESULTS: Nine hundred and thirty-three ART-naive and 1655 ART-experienced PWH initiated BIC/FTC/TAF. Over a median follow-up of 69.8 weeks, 89 (9.6%) PWH at their first regimen experienced TF. PWH aged >50 years had 1.83-fold (95% CI: 1.19-2.83) higher risk of TF; PWH with advanced HIV disease had 2.21-fold (95% CI: 1.53-3.82) higher risk; there were no differences in TF according to sex.Over a median follow-up of 146.3 weeks, 109 (6.6%) out of 1655 switching PWH experienced TF; no differences were found in the risk of TF, TDT and VF according to groups of interest. CONCLUSIONS: Overall, BIC/FTC/TAF is well tolerated and virologically effective in the real-world scenario for ART-naive and -experienced PWH. Older ART-naive PWH and those with advanced HIV disease may respond less well as the burden of diseases might compromise treatment efficacy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. d'Arminio Monforte A, Tavelli A, Di Biagio A, et al. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort. J Antimicrob Chemother. 2024. PMID: 38581349. doi:10.1093/jac/dkae081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。